30th June 2022 – VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, today announces that it has identified six NHS hospitals across England, Scotland and Northern Island for the multi-centre Phase Ib dose escalation and dose-expansion clinical trial of NG11-2, for the prevention of severe radiation-induced oral mucositis (RIOM) in head-and-neck cancer patients. Furthermore, we are pleased to announce the appointment of Dr Mary Lei at Guy’s and St Thomas’ Hospital as Chief Investigator for the trial.
Ningfeng Fiona Li, CEO of VasoDynamics, said:
“We are delighted to have gained such broad support for our NG11-2 programme from leading cancer radiotherapy centres across the UK. NG11-2, an innovative and patient-friendly mouthwash pharmaceutical formulation, represents a potential transformative solution for the cost-effective prevention of severe radiation-induced oral mucositis (RIOM) in cancer patients.”
For enquiries, please contact:
Ningfeng Fiona Li, CEO +44 7969132263
Gary Bower, COO +44 7960388412
Notes to Editors:
VasoDynamics is a UK-based pharmaceutical development company focused on improving the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, VasoDynamics is developing cost-effective medicines for the prevention and treatment of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy-induced mucositis, dermatitis and hair-loss. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculature to achieve the most effective protection of normal tissue during cancer treatment whilst enhancing anti-cancer therapy efficacy.